论文部分内容阅读
最近 ,有关两种ＣＯＸ 2抑制剂塞来克西 (ｃｅｌｅ ｃｏｘｉｂ ,Ｃｅｌｅｂｒｅｘ)和罗非克西 (ｒｏｆｅｃｏｘｉｂ ,Ｖｉｏｘｘ)的长期研究数据表明 ,与传统的非甾体抗炎药 (ＮＳＡＩＤ)相比 ,这两种药物具有较好的胃肠道安全性 ,将严重胃肠道并发症的危险性降低了一半。即使
More recently, long-term data on the two COX 2 inhibitors celecoxib (Celebrex) and rofecoxib (Vioxx) have shown that compared to conventional NSAIDs, Both drugs have good gastrointestinal safety, reducing the risk of serious gastrointestinal complications in half. even if